Jump to content
Sclero Forums

Search the Community

Showing results for tags 'dmards'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Found 9 results

  1. Metabolic and cardiovascular benefits of hydroxychloroquine (HCQ) in patients with rheumatoid arthritis (RA) : a systematic review and meta–analysis. HCQ may benefit the metabolic profile and to a lesser extent cardiovascular events in patients with RA, which suggests its usefulness combined with other conventional synthetic disease–modifying antirheumatic drugs. PubMed, Ann rheumatologist Dis, 09/25/2017. (Also see DMARDs and Treatments for Rheumatoid Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. Evaluation of a patient decision aid (PtDA) for initiating disease modifying anti–rheumatic drugs. The PtDA can be a valuable aid in improving patient participation in decision–making about disease modifying anti–rheumatic drugs (DMARDs). BioMed Central, Arthritis Research & Therapy, 10/28/2016. (Also see DMARDs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  3. Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction (MI) in rheumatoid arthritis. C–reactive protein (CRP) was associated with risk of MI and the results underline the importance of tight disease control taking not only global disease activity, but also CRP as an individual marker into account. Bio Med Central, Arthritis Research & Therapy, 08/05/2016. (Also see Symptoms and Complications of Rheumatoid Arthritis and DMARDs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  4. Treatment patterns and costs for anti–TNFα biologic therapy in patients with psoriatic arthritis. While the majority of patients received only one line of anti–TNFα therapy, a subset of patients switched to multiple lines of therapy during the 3–year follow-up period. BMC Musculoskeletal Disorders, 06/14/2016. (Also see Psoriasis and Psoriatic Arthritis and DMARD's) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  5. Safety of treatments for primary Sjögren’s syndrome. Synthetic DMARDs have not shown much efficacy in earlier studies, while biologic DMARDs show promising results regarding efficacy and cause mostly mild adverse events. PubMed, Expert Opin Drug Saf, 01/25/2016. (Also see Treatments for Symptoms of Sjögren’s Syndrome and DMARDs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  6. Antimalarial Drugs Alone may Still Have a Role in Rheumatoid Arthritis (RA). There are some patients with confirmed RA who respond well to antimalarials alone, although it is hard to objectively measure whether other factors are contributing to a good treatment response. Medscape, J Clin Rheumatol, 2015;21(4):193–195. (Also see DMARDs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  7. Just How Common Is Hydroxychloroquine (HCQ) Retinopathy? There remains considerable debate about the safety of HCQ and the exact prevalence of retinopathy resulting from its use. Medscape, 04/07/2015. (Also see DMARD's) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  8. Joint damage progression in patients with rheumatoid arthritis in clinical remission. Do biologics perform better than synthetic antirheumatic drugs? This observational study confirms that the rate of structural damage progression in clinical remission is decreased taking biologics compared to synthetic DMARD. However, while the difference is statistically significant it is probably not relevant from a clinical perspective. PubMed, J Rheumatol, 2014 Aug;41(8):1576-82. (Also see: Rheumatoid Arthritis Treatments, Biologic Agents and Disease-modifying Antirheumatic Drugs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  9. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs(sDMARDs and bDMARDs): 2013 update. EULAR's most recent consensus on the management of RA with sDMARDs, glucocorticoids and bDMARDs. PubMed, Ann rheumatologist Dis, 2013 Oct 25. (Also see: Rheumatoid Arthritis Treatments and DMARDs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
×